Back to top
more

Cynata Therapeutics (CYYNF)

(Delayed Data from OTC)

$0.19 USD

0.19
NA

0.00 (0.00%)

Updated Jun 13, 2024 02:41 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Cynata Therapeutics Ltd. [CYYNF]

Reports for Purchase

Showing records 1 - 20 ( 35 total )

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 1

01/23/2023

Company Report

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 2

11/23/2020

Company Report

Pages: 4

High-Profile Licensing Deal Underscores Cell Therapy Value; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 3

11/11/2020

Company Report

Pages: 4

CYP-004 Phase 3 SCUlpTOR Trial Commences; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 4

08/03/2020

Company Report

Pages: 4

Positive CYP-001 Two-Year Long-Term Follow-Up Clinical Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 5

06/22/2020

Company Report

Pages: 5

Clinical Progress on Multiple Fronts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 6

12/16/2019

Company Report

Pages: 5

Preclinical Sepsis Data Hint at Therapeutic Potential; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 7

10/18/2019

Company Report

Pages: 4

Dainippon Sumitomo Takeover Bid Withdrawn; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 8

09/18/2019

Company Report

Pages: 5

FUJIFILM Exercises Option; Dainippon Sumitomo Acquisition Offer Remains Pending; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 9

03/22/2019

Company Report

Pages: 4

FUJIFILM Delay Merely a Bump in the Road, We Believe; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 10

12/14/2018

Company Report

Pages: 5

Research Funding Awarded; Tax Credits Received; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 11

09/17/2018

Company Report

Pages: 4

Recent Developments Underscore Clinical Progress; FUJIFILM May Exercise Option Soon; Raising Target to A$2

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 12

08/30/2018

Company Report

Pages: 4

CYP-001 Meets Safety and Efficacy Endpoints in Phase 1 Graft-vs.-Host Disease Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 13

05/29/2018

Company Report

Pages: 4

CYP-001 Phase 1 Trial Enrollment Completed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 14

04/02/2018

Company Report

Pages: 4

FDA Grants CYP-001 Orphan Drug Designation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 15

02/28/2018

Company Report

Pages: 4

Cohort A Primary Evaluation Period Data Comes up Trumps; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 16

01/22/2018

Company Report

Pages: 4

Data Safety Monitoring Board Clears Trial to Enter Cohort B; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 17

11/20/2017

Company Report

Pages: 4

First Cohort Enrollment Completed in CYP-001 Clinical Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 18

09/08/2017

Company Report

Pages: 4

Upcoming Milestones Could Prove Transformative; Reiterate Buy and Raising Target to A$1.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 19

03/02/2017

Company Report

Pages: 4

Advances in Asthma; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Cynata Therapeutics Ltd.

Industry: Medical - Biomedical and Genetics

Record: 20

03/02/2017

Company Report

Pages: 4

Advances in Asthma; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party